Accept Volatility in Moderna As It Should Prevail in Time
InvestorPlace - Stock Market News, Stock Advice & Trading Tips There's no need to abandon MRNA stock now as Moderna remains an aggressive pioneer in advancing mRNA therapeutics. The post...
In combating the global spread of Covid-19 since March of 2020, Moderna (NASDAQ:MRNA) has taken center stage. As a result, patient investors have done well with a position in MRNA stock.
On the other hand, not every day is a great day to be invested in Moderna. There will be good days and bad days, and the shareholders should get used to sudden moves along the way to eventual higher prices.
That’s how it goes in the world of pharmaceutical stocks. Since August, MRNA stock has jumped around, shaking less experienced investors out of the trade.
We’ll take a closer look at the price action in a moment. Just as importantly, though, Moderna’s long-term outlook is bright as the company continued to prove itself as a leader in the worldwide battle against Covid-19.
MRNA Stock at a Glance
It’s amazing to consider that MRNA stock started off 2021 at the $122 level. By the end of September, it would literally triple in price.
The shareholders who held on throughout the summer enjoyed the lion’s share of the gains. In early August, the stock flew to a 52-week high of nearly $500.
Today, we might consider $500 as a resistance level. That’s because MRNA stock was rejected there several times, including a couple of attempts to break through in September.
Along the way, there have been some sharp price moves, sometimes of $5 or more in a single trading session. Pharmaceutical stocks tend to exhibit volatility when there are news events, and it seems like there’s always something going on with Moderna.
So, keep your eye out for new developments with MRNA stock — and don’t feel the need to sell your shares every time the stock falls 5%.
Protecting the Youth – and Adults Too
It’s interesting that at one time, there was a widespread perception that children were immune to the impact of Covid-19.
Today, there is a better understanding of Covid-19’s effects on various demographics. With this comes the realization that children can be susceptible to Covid-19.
Thankfully, Moderna’s pioneering messenger RNA therapeutics and vaccines aren’t only developed to protect adults.
As evidence of this, Moderna recently revealed that Health Canada approved the New Drug Submission for Spikevax.
This is a messenger RNA vaccine, which is also known as Covid-19 Vaccine Moderna. In this instance, it has been developed for active immunization to prevent Covid-19 in individuals 12 years of age and older.
The vaccine was originally authorized in Canada in December under an Interim Order for individuals 18 years of age and older.
A Phase 3 COVE study of the vaccine, which enrolled more than 30,000 participants in the U.S. showed 93% efficacy for Spikevax. Furthermore, the efficacy endured through six months after administration of the second dose.
Pursuing Approval Globally
The aforementioned news item only applies to Canada.
However, Moderna is working aggressively to get its Covid-19 vaccine into the hands of people who need it, in various regions of the world.
For instance, Moderna just announced a supply agreement with the government of Peru. This deal specifically calls for 20 million doses of the company’s Covid-19 vaccine to be distributed.
Delivery of the vaccine is slated to begin during the first quarter of 2022.
The Covid-19 Vaccine Moderna isn’t currently approved for use in Peru. However, the company intends to work with regulators to pursue the necessary approvals prior to distribution.
“We are committed to making our vaccine available around the world as we seek to address the pandemic with our COVID-19 vaccine,” commented Moderna Chief Commercial Officer Corinne Le Goff.
All in all, you’d be hard-pressed to find a more ambitious Covid-19 vaccine manufacturer than Moderna.
As for MRNA stock, it performed well through much of 2021.
Given the company’s impressive progress in battling Covid-19, don’t be surprised if the shareholders enjoy a solid finish to the year.
On the date of publication, neither Louis Navellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article.
Louis Navellier, who has been called “one of the most important money managers of our time,” has broken the silence in this shocking “tell all” video… exposing one of the most shocking events in our country’s history… and the one move every American needs to make today.
More From InvestorPlace
- Stock Prodigy Who Found NIO at $2… Says Buy THIS Now
- Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom
- America’s #1 EV Stock Still Flying Under the Radar
The post Accept Volatility in Moderna As It Should Prevail in Time appeared first on InvestorPlace.